Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Keros Therapeutics Inc (KROS)

Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Keros Therapeutics Inc 1050 WALTHAM STREET SUITE 302 LEXINGTON MA 02421 USA

www.kerostx.com Employees: 169 P: 617-314-6297

Sector:

Medical

Description:

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage. Keros Therapeutics, Inc. is based in LEXINGTON, MA.

Key Statistics

Overview:

Market Capitalization, $K 646,793
Enterprise Value, $K 86,863
Shares Outstanding, K 30,466
Annual Sales, $ 3,550 K
Annual Net Income, $ -187,350 K
Last Quarter Sales, $ 14,260 K
Last Quarter Net Income, $ -7,280 K
EBIT, $ 43,590 K
EBITDA, $ 44,820 K
60-Month Beta 0.89
% of Insider Shareholders 22.90%
% of Institutional Shareholders 71.56%
Float, K 23,489
% Float 77.10%
Short Interest 3,229
Short Float 10.60%
Short Volume Ratio 0.51

Growth:

1-Year Return 10.87%
3-Year Return -54.53%
5-Year Return -72.97%
5-Year Revenue Growth -64.50%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.18 on 11/05/25
Next Earnings Date 02/25/26
Earnings Per Share ttm 1.54
EPS Growth vs. Prev Qtr 76.32%
EPS Growth vs. Prev Year 87.23%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

KROS Ratios

Ratio
Price/Earnings ttm 13.97
Price/Earnings forward 9.55
Price/Earnings to Growth 0.26
Return-on-Equity % 9.51%
Return-on-Assets % 8.89%
Profit Margin % -5,277.47%
Debt/Equity 0.00
Price/Sales 184.60
Price/Cash Flow N/A
Price/Book 0.93
Book Value/Share 23.09
Interest Coverage -3.59
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar